Apellis Pharmaceuticals Inc (APLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Sales | 250,646 | 0 | 0 | 0 | 0 |
| Cost of Goods | 25,050 | N/A | N/A | N/A | N/A |
| Gross Profit | 225,596 | N/A | N/A | N/A | N/A |
| Operating Expenses | 439,372 | 288,015 | 127,925 | 50,767 | 27,282 |
| Operating Income | -213,726 | -288,015 | -127,925 | -50,767 | -27,282 |
| Interest Expense | 29,937 | 5,285 | 2,513 | 375 | 0 |
| Other Income | -99,366 | -11,407 | 2,936 | 136 | 158 |
| Pre-tax Income | -343,029 | -304,707 | -127,502 | -51,006 | -27,125 |
| Income Tax | 1,845 | N/A | N/A | N/A | N/A |
| Net Income Continuous | -344,874 | -304,707 | -127,502 | -51,006 | -27,125 |
| Net Income | $-344,874 | $-304,707 | $-127,502 | $-51,006 | $-27,125 |
| EPS Basic Total Ops | -4.59 | -4.90 | -2.34 | -3.68 | -3.22 |
| EPS Basic Continuous Ops | -4.59 | -4.90 | -2.34 | -3.68 | -3.22 |
| EPS Diluted Total Ops | -4.59 | -4.90 | -2.34 | -3.68 | -3.22 |
| EPS Diluted Continuous Ops | -4.59 | -4.90 | -2.34 | -3.68 | -3.22 |
| EPS Diluted Before Non-Recurring Items | -4.59 | N/A | N/A | N/A | N/A |
| EBITDA(a) | $-197,331 | $-285,077 | $-127,343 | $-50,755 | $-27,282 |